CTLA4 and neoplasm: Recently, immune checkpoint inhibitors targeting programmed cell death 1 and its ligand (PD-1/PD-L1) and Cytotoxic T-lymphocyte antigen-4 (CTLA-4) have shown promising preliminary results in various tumours.